Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 years or older
- People with a confirmed diagnosis of stage IIIC or stage IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma
- People whose scans (CT or PET/CT) show a low, medium, or high tumour spread, but with a specific spread score of 12 or below
- People whose scans suggest that complete removal of visible tumour during surgery is likely to be achievable
- People who agree to undergo genetic testing for BRCA (breast cancer gene) and HRD (a marker of how cancer cells repair DNA)
- People with a reasonably good general health and activity level (confirm with trial site for exact definition)
- People whose blood tests show that bone marrow, kidney, and liver are functioning well enough to safely receive chemotherapy and surgery (the trial site will assess specific blood test values)
- People who are willing and able to follow the study procedures and attend follow-up appointments
- People who have given written consent to participate in the trial
Who may not be able to join:
- People whose ovarian cancer is not of the epithelial type, or whose tumour is classified as "borderline"
- People with low-grade ovarian cancer
- People with mucinous ovarian cancer
- People whose scans suggest that complete tumour removal is not achievable — for example, due to cancer that has spread into the lung tissue, liver tissue, the lining around the lungs (in ways that cannot be surgically addressed), multiple chest lymph nodes, the brain, or bones
- People with a known allergy or sensitivity to olaparib, bevacizumab, or any of their ingredients
- People who have had another cancer diagnosis within the past 5 years — exceptions may apply for certain early-stage or non-active cancers such as thyroid cancer, early-stage breast cancer with no signs of return, or carcinoma in situ (confirm with trial site)
- People with other medical conditions that would make surgery or chemotherapy unsafe or that would make it difficult to follow the study plan
- People with other factors — such as psychological, religious, or personal circumstances — that may prevent them from giving informed consent or following through with study procedures and follow-up
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Libing Xiang, Fudan University
Phone: 86 21 64041990
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
3-year overall survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.